Hester Biosciences Limited has informed the Exchange that Board of Directors at its meeting held on May 09, 2025, recommended Final Dividend of Rs. 7 per equity share.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences' Board approved audited standalone and consolidated financial results for Q4 and FY ended 31 March 2025, with statutory auditors issuing an unmodified opinion. The Board recommended a final dividend of Rs. 7 per equity share (70% on face value of Rs. 10), subject to shareholder approval. On a consolidated basis, revenue from operations grew modestly to Rs. 3,111.02 million (vs Rs. 3,045.46 million in FY24, up ~2.2%), while profit after tax jumped ~36% to Rs. 288.26 million (vs Rs. 211.66 million). Standalone revenue was nearly flat at Rs. 2,864.66 million, but standalone PAT rose ~17% to Rs. 318.42 million. The company also appointed Shah & Shah Associates as Secretarial Auditor for FY 2025-26 to FY 2029-30. Operating cash flow remained strong at Rs. 645.11 million on a consolidated basis.
Positive for shareholders — a healthy dividend payout, clean audit opinion, and strong consolidated profit growth signal stable operations, though standalone revenue growth was muted and ongoing capital expenditure on the BSL-3 facility continues to absorb cash.